Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (1629)	12/17/2005 8:05:57 PM
From: Robohogs	Respond to of 1826

Anyone think this bounces after tax and disappointment selling has driven it too low? Jon

To: Icebrg who wrote (1629)	12/19/2005 10:42:34 AM
From: Icebrg	Read Replies (1) \| Respond to of 1826

MGI PHARMA "outperform," target price reduced Monday, December 19, 2005 9:11:44 AM ET RBC Capital Markets NEW YORK, December 19 (newratings.com) - Analyst David Bouchey of RBC Capital Markets reiterates his "outperform" rating on MGI PHARMA Inc (MOGN.NAS). The target price has been reduced from $35 to $33. In a research note published on December 16, the analyst mentions that the FDA’s decision on the company’s Dacogen drug is not expected until May 15, 2006. Due to the delay in the review process, MGI PHARMA is unlikely to launch the drug by 3Q, as compared to the expectations of a 1Q launch, the analyst says. The company’s stock is currently undervalued, even after considering the delay in the approval of Dacogen, RBC Capital Markets adds.